Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

Inclusion Criteria

• •Inclusion
• •Histologically confirmed medullary thyroid cancer
• •Metastatic or inoperable locoregional disease
• •Measurable disease by CT scan
• •18 years and over
• •ECOG PS 0-1
• •Adequate lab functions including:
• •Granulocyte count \> 1,000/mm\^3
• •Platelet count \> 100,000/mm\^3
• •Bilirubin \< 1.5 mg/dL
• •ALT and AST \< 2.5 times upper limit of normal
• •No unstable or uncompensated hepatic disease
• •Creatinine clearance \> 60 mL/min
• •No unstable or uncompensated renal disease
• •Negative pregnancy test
• •More than 3 months since prior biologic therapy
• •More than 3 months since prior chemotherapy
• •No prior radiotherapy to \> 25% of bone marrow
• •More than 3 months since prior radiotherapy
• •Recovered from prior oncologic or other major surgery
• •More than 30 days since prior non-approved or investigational drugs
• •Exclusion: